AGC Biologics develops and manufactures diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. Our quality systems, facility layout and regulatory qualifications enable us to serve both clinical and commercial demands. Since we perform more than 100 analytical tests in-house, AGC Biologics reduces overall turnaround time. With experience manufacturing three commercial products, we are the only cell and gene therapy CDMO that has brought its own product to the market (Zalmoxis®).